Amisulpride

Indications & formulation #

Schizophrenic disorders in adults. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral tablet; UK SmPC · United Kingdom. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

Acute positive symptoms: 400–800 mg/day; maximum 1200 mg/day. Predominant negative symptoms: 50–300 mg/day. Divide doses above 400 mg/day.

Contraindications & important cautions #

Contraindications include prolactin-dependent tumors, phaeochromocytoma and levodopa. Review QT, prolactin and neuroleptic malignant syndrome.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Prolactin elevation, movement symptoms and QT prolongation.

Interactions #

Levodopa is contraindicated; review QT-prolonging combinations.

Monitoring #

Monitor renal function, movements, prolactin symptoms and cardiac risk.

Special populations #

CrCl 30–60: half dose; 10–30: one-third dose. Below 10, evidence is insufficient. Older adults need particular caution.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Withdraw gradually. This oral reference does not derive from the US intravenous antiemetic product.

Brands & products #

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.